Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Patients
Status:
Recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability, and pharmacokinetics (PK) of cefiderocol after
single-dose administration in hospitalized pediatric patients 3 months to < 12 years of age
with suspected or confirmed aerobic Gram-negative bacterial infections and after
multiple-dose administration in hospitalized pediatric patients 3 months to < 18 years of age
with suspected or confirmed complicated urinary tract infection (cUTI), hospital-acquired
pneumonia (HAP), or ventilator-associated pneumonia (VAP).